Tag: clinical stage immuno-oncology company

June 10, 2018

5 Top Weekly NASDAQ Biotech Stocks: MEI Pharma on Top

MEI Pharma, Anavex Life Sciences, Trillium Therapeutics, Celldex Therapeutics and Ophthotech were last week's top gainers on the NASDAQ Biotechnology...
April 29, 2018

5 Top Weekly NASDAQ Biotech Stocks: Eleven Biotherapeutics Up 45 Percent

Eleven Biotherapeutics, EyePoint Pharmaceuticals, Avid Bioservices, Cerecor and Celldex were last week's top gainers on the NASDAQ.
April 26, 2018

Merus Announces Recent Corporate Developments and Financial Results for the Fourth Quarter and Full Year 2017

Merus (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced financial results for the fourth quarter...
April 24, 2018

Immunovaccine and Incyte Expand Clinical Collaboration Evaluating Combination Immunotherapies in Advanced Recurrent Ovarian Cancer

Immunovaccine (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that it has entered into an agreement with Incyte Corporation...
April 19, 2018

Surface Oncology Announces $119.5 Million Aggregate Financing

Surface Oncology (Nasdaq:SURF), a clinical-stage immuno-oncology company developing next-generation antibody therapies that target the tumor microenvironment, today announced the pricing...
April 16, 2018

New Preclinical Studies Reinforce the Potential for Heightened Anti-Cancer Activity of Combination Therapies Based on Immunovaccine’s Proprietary Delivery Platform

Immunovaccine (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that it presented new research on its T-cell activating platform...
April 10, 2018

Trillium Therapeutics Provides Update on Its TTI-621 and TTI-622 Clinical Programs

Trillium Therapeutics (Nasdaq:TRIL) a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided the following update on...